Type 2 diabetes market heats up

Despite the variety of efficacious oral anti-diabetics available to treat type 2 diabetes—many of them available generically—the unmet need in this disease remains high.

Merck’s Januvia (sitagliptin), which was firstly introduced to the Korean market as the newest class of agents to treat this disease, the dipeptidyl peptidase-IV (DPP-IV) inhibitors, led the local anti-diabetics market.

J...